Live Breaking News & Updates on Translational Research In Normal Disordered Development

Stay updated with breaking news from Translational research in normal disordered development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

UAB spinoff receives $3 million in seed funding to develop probiotic formulations for lung health

UAB spinoff receives $3 million in seed funding to develop probiotic formulations for lung health
A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding.
ResBiotic Inc. spun off from UAB last year will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the UAB Department of Pediatrics, Division of Neonatology. The seed round was funded from a private equity syndicate led by Birmingham-based investment firm Timberline Holdings.
ResBiotic s first product aims to supplement the nutritional needs in chronic lung diseases. The product was developed in Lal s Pulmonary Microbiome Lab at UAB, with research and expertise from UAB s Microbiome Center, Lung Health Center, and the Translational Research in Normal & Disordered Development program. ....

Namasivayam Ambalavanan , Andrew Oconnor , C Vivek Lal , Jon Nugent , Braxton Goodrich , Emily Henderson , Scott Bush , Amit Gaggar , Sanjay Singh , Microbiome Center , Birmingham Business Alliance , Resbiotic Inc , Division Of Neonatology , Lal Pulmonary Microbiome Lab , Resbiotech Innovation Institute , University Of Alabama At Birmingham , Timberline Holdings , Department Of Cell , Division Of Pulmonary , Translational Research In Normal Disordered Development , Department Of Pediatrics , Department Of Medicine , Lung Health Center , Pulmonary Microbiome Lab , Translational Research , Disordered Development ,

UAB spinoff to treat chronic respiratory disease announces $3 million seed funding

Credit: UAB
BIRMINGHAM, Ala. - A biomedical research company founded by a University of Alabama at Birmingham physician-scientist has received $3 million in seed funding.
ResBiotic Inc. spun off from UAB last year will use the money to develop and commercialize groundbreaking probiotic formulations for lung health, says founder C. Vivek Lal, M.D., an associate professor in the UAB Department of Pediatrics, Division of Neonatology. The seed round was funded from a private equity syndicate led by Birmingham-based investment firm Timberline Holdings.
ResBiotic s first product aims to supplement the nutritional needs in chronic lung diseases. The product was developed in Lal s Pulmonary Microbiome Lab at UAB, with research and expertise from UAB s Microbiome Center, Lung Health Center, and the Translational Research in Normal & Disordered Development program. ....

Namasivayam Ambalavanan , Andrew Oconnor , C Vivek Lal , Jon Nugent , Braxton Goodrich , Scott Bush , Amit Gaggar , Sanjay Singh , Microbiome Center , Resbiotic Inc , Division Of Neonatology , Lal Pulmonary Microbiome Lab , Innovation For The Birmingham Business Alliance , Resbiotech Innovation Institute , University Of Alabama At Birmingham , Timberline Holdings , Department Of Cell , Division Of Pulmonary , Translational Research In Normal Disordered Development , Department Of Pediatrics , Department Of Medicine , Lung Health Center , Pulmonary Microbiome Lab , Translational Research , Disordered Development , Innovation Depot ,